FDA Authorizes Second COVID-19 Vaccine After Moderna Review

The US has set a new record for daily COVID-19 infections. The Moderna vaccine has received emergency use authorization, allowing for millions of doses to be distributed across the country. This follows the rollout of Pfizer's vaccine. Both vaccines require two doses and are over 90% effective. Moderna's vaccine, unlike Pfizer's, does not need extreme cold storage, making it more accessible to rural areas. Initial vaccinations will target frontline workers and high-risk groups, but supply is insufficient for all healthcare workers. Other professions are lobbying for inclusion in future rounds. States are receiving fewer Pfizer doses than expected, and it will take at least six months for widespread vaccination.

What is the effectiveness rate of both the Moderna and Pfizer vaccines in preventing COVID-19?

• Around 60%

• More than 90%

• Less than 50%

• Exactly 75%

Why is Moderna's vaccine considered more suitable for rural areas compared to Pfizer's?

• It is cheaper to produce.

• It requires less frequent doses.

• It is more effective in rural populations.

• It does not need extreme cold storage.

Who are the first groups expected to receive the COVID-19 vaccines?

• Only healthcare workers

• Frontline responders and the elderly

• Children and teenagers

• All citizens over 18

Which professions are lobbying to be included in the next round of vaccinations?

• Restaurant workers and Uber drivers

• Teachers and students

• Government officials

• Tech industry employees

When are most Americans expected to be vaccinated according to health experts?

• By the end of 2022

• By the end of 2021

• In the next six months

• Within the next three months